Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENVARSUS vs Prograf to prevent post-transplant diabetes in renal transplant recipients at risk
2017-000718-52Phase 4Active
- Sponsor
- Hospital Universitario de Canarias
- Start
- Mar 2017
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in diabetes mellitus (DM) and end-stage kidney disease (ESKD) (2 arms), sponsored by Hospital Universitario de Canarias. Primary endpoint: diabetes post-transplant incidence. Started Mar 2017; status: active.
02
Drugs
tacrolimus
03
Conditions
diabetes mellitus (DM)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2017-000718-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000718-52.